Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: Impact of the WHI reports

Climacteric

Volumn 9, Issue 3, 2006, Pages 224-233

  Gambrell Jr , R D ^a,b   Natrajan, P K ^a  

^a Reproductive Endocrinologists   (United States)

^b NONE   (United States)

Author keywords

Continuation rates; Moderate dosage HRT; Postmenopausal

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL CIPIONATE; ESTRATEST; ESTROGEN; GESTAGEN; HYDROCHLOROTHIAZIDE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; PROGESTERONE; SPIRONOLACTONE; TESTOSTERONE; TESTOSTERONE CIPIONATE;

ARTICLE; BLOATING; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; DEPRESSION; EDEMA; ENDOMETRIUM CANCER; FEMALE; HEADACHE; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; IRRITABILITY; LETHARGY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; WELLBEING;

ADULT; AGED; AGED, 80 AND OVER; DRUG IMPLANTS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOT FLASHES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT DROPOUTS; PREVALENCE; PROGESTINS; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 33646714434     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130600643437     Document Type: Article

References (20)

1. Ettinger B, Li DK, Klein R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Menopause 1996;3:185-9
2. Hill DA, Wiess NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol 2000;182:270-6
3. Berman RS, Epstein RS, Lydick EG. Risk factors associated with women's compliance with estrogen replacement therapy. J Women's Health 1997;6:219-26
4. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-4
5. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999;6:273-6
6. Studd J. Editorial. Continuation rates with cyclical and continuous regimens of oral estrogens and progestogens. Menopause 1996;3:181-2
7. Khastgie G, Studd J. Patients' outlook, experience and satisfaction with hysterectomy, bilateral oophorectomy and subsequent continuation of hormone replacement therapy. Am J Obstet Gynecol 2000;183:1427-33
8. Gambrell RD Jr. Management of hormone replacement side effects. Menopause 1994;1:67-72
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from The Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
10. Gambrell RD Jr. Estrogen Replacement Therapy User Guide. Durant, Oklahoma: Essential Medical Information Systems, Inc, 1997:1-117
11. Gambrell RD Jr. Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol 1997;177:1196-207
12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1702-12
13. Watts NB, Notelovitz M, Timmons MC, et al. Comparison of oral estrogens and estrogen plus androgen on bone mineral density, menopausal symptoms, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529-37
14. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-60
15. Greenblatt RB. The use of androgens in the menopause and other gynecologic disorders. Obstet Gynecol Clin N Am 1987;14:251-68
16. Corson SL, Richart RM, Caubel PC, et al. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17β-estradiol and norgestimate on endometrial histology. Int J Fertil 1999;44:279-85
17. Cameron ST, Critchley HOD, Glasier AF, et al. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Br J Obstet Gynaecol 1997;104:1184-90
18. Position Statement of the Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopause transition and beyond. Climacteric 2004;7:8-11
19. Natrajan PK, Gambrell RD Jr. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002;187:289-95
20. Gambrell RD Jr. Hormone replacement therapy and breast cancer risk. Arch Fam Med 1996;5:341-8